Myxoma virus is a pathogenic poxvirus that induces a lethal myxomatosis disease profile in European rabbits, which is characterized by fulminating lesions at the primary site of inoculation, rapid dissemination to secondary internal organs and peripheral external sites, and supervening gram-negative bacterial infection. Here we describe the role of a novel myxoma virus protein encoded by the M-T5 open reading frame during pathogenesis. The myxoma virus M-T5 protein possesses no significant sequence homology to nonviral proteins but is a member of a larger poxviral superfamily designated host range proteins. An M-T5- mutant virus was constructed by disruption of both copies of the M-T5 gene followed by insertion of the selectable marker p7.5Ecogpt. Although the M-T5- deletion mutant replicated with wild-type kinetics in rabbit fibroblasts, infection of a rabbit CD4+ T-cell line (RL5) with the myxoma virus M-T5- mutant virus resulted in the rapid and complete cessation of both host and viral protein synthesis, accompanied by the manifestation of all the classical features of programmed cell death. Infection of primary rabbit peripheral mononuclear cells with the myxoma virus M-T5-mutant virus resulted in the apoptotic death of nonadherent lymphocytes but not adherent monocytes. Within the European rabbit, disruption of the M-T5 open reading frame caused a dramatic attenuation of the rapidly lethal myxomatosis infection, and none of the infected rabbits displayed any of the characteristic features of myxomatosis. The two most significant histological observations in rabbits infected with the M-T5-mutant virus were (i) the lack of progression of the infection past the primary site of inoculation, coupled with the establishment of a rapid and effective inflammatory reaction, and (ii) the inability of the virus to initiate a cellular reaction within secondary immune organs. We conclude that M-T5 functions as a critical virulence factor by allowing productive infection of immune cells such as peripheral lymphocytes, thus facilitating virus dissemination to secondary tissue sites via the lymphatic channels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC190373PMC
http://dx.doi.org/10.1128/JVI.70.7.4394-4410.1996DOI Listing

Publication Analysis

Top Keywords

myxoma virus
24
virus
12
disruption m-t5
8
novel myxoma
8
host range
8
dramatic attenuation
8
european rabbits
8
lethal myxomatosis
8
primary site
8
site inoculation
8

Similar Publications

Modified Vaccinia Virus Ankara Selectively Targets Human Cancer Cells With Low Expression of the Zinc-Finger Antiviral Protein.

J Med Virol

January 2025

National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.

Oncolytic viruses are emerging as promising cancer therapeutic agents, with several poxviruses, including vaccinia virus (VACV) and myxoma virus, showing significant potential in preclinical and clinical trials. Modified vaccinia virus Ankara (MVA), a laboratory-derived VACV strain approved by the FDA for mpox and smallpox vaccination, has been shown to be incapable of replicating in human cells unless zinc finger antiviral protein (ZAP) is repressed. Notably, ZAP deficiency is prevalent in various cancer types.

View Article and Find Full Text PDF

Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy.

Methods Mol Biol

December 2024

Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.

Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs.

View Article and Find Full Text PDF

Evaluation of dried blood spots for serological surveys of myxoma and rabbit hemorrhagic disease viruses in their wild reservoir.

Prev Vet Med

January 2025

CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, InBIO Laboratório Associado, Universidade do Porto, Campus de Vairão, Vairão 4485-661, Portugal; BIOPOLIS Program in Genomics, Biodiversity and Land Planning, CIBIO, Campus de Vairão, Vairão 4485-661, Portugal; Estação Biológica de Mértola (EBM), CIBIO, Praça Luís de Camões, Mértola 7750-329, Portugal. Electronic address:

Article Synopsis
  • Myxoma (MYXV) and rabbit hemorrhagic disease (RHDV) viruses are significant threats to European rabbits, which are now considered 'Endangered' in their native habitat.
  • The study focused on evaluating the effectiveness of dried blood spots (DBS) for serological surveys of these viruses in European rabbits by comparing DBS to traditional serum samples.
  • Results showed a high level of agreement between the two methods, with DBS demonstrating strong diagnostic sensitivity and perfect specificity for both MYXV and RHDV, confirming its viability for monitoring these diseases in the wild rabbit population.
View Article and Find Full Text PDF

Treatment of glioblastoma is ineffective. Myx-M011L-KO/EGFP, a myxoma virus actively inducing apoptosis in BTICs linked to recurrence, offers innovative treatment. We loaded this construct into adipose-derived stem cells (ADSCs) to mitigate antiviral host responses and enable systemic delivery.

View Article and Find Full Text PDF

Cytokine therapy represents an attractive option to improve the outcomes of cancer patients. However, the systemic delivery of these agents often leads to severe immune-related toxicities, which can prevent their efficient clinical use. One approach to address this issue is the use of recombinant oncolytic viruses to deliver various cytokines directly to the tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!